Clearmind Medicine Inc. CMND
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -95.71%
- 1 year
- -99.79%
- Open
- 5.83
- Prev close
- 5.85
- Mkt cap
- 3.16M
- Vol
- 10.47K
- Avg vol
- 58.53K
- EPS
- -461.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.83
- High
- 6.50
- Forward P/E
- 0.00
- Beta
- -1.51
- Short ratio
- 1.88
- Inst. own
- 16.02%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.39
- 200-d avg
- 1.33
- 1y target
- 0.00
3M chart
Events in this range
- Oct 5, 2026Split: 1 for 8
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 4, 2026 | 1 month ago |
| RSI: Oversold | Sep 4, 2026 | 1 month ago |
| SMA: Bearish | Sep 3, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 27, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
Key statistics
- Market cap
- 5.35M
- Enterprise value
- -2.75M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.40
- EPS (TTM)
- -1.23
- Beta
- -1.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 162.86K
- Total cash
- 7.68M
- Total debt
- 60.90K
- Return on equity
- -267.90%
- Shares outstanding
- 4.38M
- Short % of float
- 4.72%
- 50-day average
- 1.39
- 200-day average
- 1.33
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Clearmind Medicine Inc.
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders; and Dr. Glitter Pty Ltd to develop and commercialize the MEAI-based alcohol substitute and ActivCrystal technology. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- clearmindmedicine.com
News
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
- Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
- Clearmind Medicine's Charging Robotics Subsidiary Rolls Out Autonomous Vehicle Charging Platform
- Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
- Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia
- Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
- Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
- Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026
- NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Your note
Sign in to keep a note on CMND — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gotham Asset Management, LP | 10.70% | 339,008 | 413.59K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 5.38% | 170,641 | 208.18K | Sep 29, 2024 |
| UBS Group AG | 4.46% | 141,337 | 172.43K | Sep 29, 2024 |
| Cornerstone Wealth Group, LLC | 0.63% | 20,000 | 24.40K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.56% | 17,729 | 21.63K | Sep 29, 2024 |
| HRT Financial LP | 0.40% | 12,756 | 15.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 6.74% | 213,764 | 260.79K | Oct 30, 2024 |